Clinical Trial Update: Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on a Phase 1/2 study of lenalidomide in combination with obinutuzumab for relapsed indolent non-Hodgkin lymphoma, including follicular lym…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Indolent Non-hodgkin Lymphoma
• Marginal Zone Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Gazyva (Obinutuzumab)
• Revlimid (lenalidomide)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-06-24